Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients.

Antimicrob Agents Chemother

VA Boston Healthcare System, West Roxbury, Massachusetts, USA Boston University School of Medicine, Boston, Massachusetts, USA National Center for Occupational Health and Infection Control, Gainesville, Florida, USA.

Published: February 2016

Few oral antibiotics exist for the empirical treatment of extended-spectrum β-lactamase (ESBL) urinary tract infections (UTI). In this study, we sought to determine the activity of fosfomycin against ESBL-producing uropathogens from patients at 3 Veterans Affairs (VA) facilities between 2010 and 2013. Among the ESBL uropathogens, 19.9% were fosfomycin resistant. Klebsiella species were more likely than Escherichia coli to be resistant (46% versus 4%; P < 0.001). Fosfomycin remains active against a majority of the ESBL uropathogens, although resistance among Klebsiella spp. was higher than that in previous reports.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750673PMC
http://dx.doi.org/10.1128/AAC.02614-15DOI Listing

Publication Analysis

Top Keywords

activity fosfomycin
8
uropathogens patients
8
esbl uropathogens
8
fosfomycin extended-spectrum-β-lactamase-producing
4
uropathogens
4
extended-spectrum-β-lactamase-producing uropathogens
4
patients community
4
community hospitalized
4
hospitalized patients
4
patients oral
4

Similar Publications

Enterococcus species, natural inhabitants of the human gut, have become major causes of life-threatening bloodstream infections (BSIs) and the third most frequent cause of hospital-acquired bacteremia. The rise of high-level gentamicin resistance (HLGR) in enterococcal isolates complicates treatment and revives bacteriophage therapy. This study isolated and identified forty E.

View Article and Find Full Text PDF

It is established that reverse hydroxamate analogs of fosmidomycin inhibit the growth of by inhibiting 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR), the second enzyme of the non-mevalonate pathway, which is absent in humans. Recent biochemical studies have demonstrated that novel reverse fosmidomycin analogs with phenylalkyl substituents at the hydroxamate nitrogen exhibit inhibitory activities against DXR at the nanomolar level. Moreover, crystallographic analyses have revealed that the phenyl moiety of the -phenylpropyl substituent is accommodated in a previously unidentified subpocket within the active site of DXR.

View Article and Find Full Text PDF

Fluoroquinolones and Biofilm: A Narrative Review.

Pharmaceuticals (Basel)

December 2024

Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34129 Trieste, Italy.

: Biofilm-associated infections frequently span multiple body sites and represent a significant clinical challenge, often requiring a multidisciplinary approach involving surgery and antimicrobial therapy. These infections are commonly healthcare-associated and frequently related to internal or external medical devices. The formation of biofilms complicates treatment, as they create environments that are difficult for most antimicrobial agents to penetrate.

View Article and Find Full Text PDF

National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study.

Antibiotics (Basel)

November 2024

Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán", Ave. Velez Sarsfield 563, Buenos Aires City 1281, Argentina.

Unlabelled: The COVID-19 pandemic has exacerbated the global antimicrobial resistance (AMR) crisis. Consequently, it is more urgent than ever to prioritize AMR containment and support countries in improving the detection, characterization, and rapid response to emerging AMR threats. We conducted a prospective, multicenter study to assess the prevalence of carbapenemase-producing Enterobacterales in infectious processes in Argentina during the post-COVID-19 pandemic period and explore therapeutic alternatives for their treatment (RECAPT-AR study).

View Article and Find Full Text PDF

Introduction Urinary tract infections (UTIs) are one of the most common bacterial infections encountered in community and healthcare settings. Increasing antimicrobial resistance patterns worldwide have limited the treatment options available. Overuse of carbapenems which were considered as the last resort for multi-drug resistant UTIs over the past decade has led to the emergence of carbapenem-resistant Enterobacterales (CRE).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!